Dose-response of Acute Urinary Toxicity of Long-course Preoperative Chemoradiotherapy for Rectal Cancer

Overview

Journal Acta Oncol

Specialty Oncology

Date 2014 Jul 1

PMID 24975373

Citations 13

Authors

Ane L Appelt

Soren M Bentzen

Anders Jakobsen

Ivan R Vogelius

Affiliations

Soon will be listed here.

Abstract

Background: Long-course preoperative chemoradiotherapy (chemo-RT) improves outcomes for rectal cancer patients, but acute side effects during treatment may cause considerable patient discomfort and may compromise treatment compliance. We developed a dose-response model for acute urinary toxicity based on a large, single-institution series.

Material And Methods: In total 345 patients were treated with (chemo-)RT for primary rectal cancer from January 2007 to May 2012. Urinary toxicity during RT was scored prospectively using the CTCAE v 3.0 cystitis score (grade 0-5). Clinical variables and radiation dose to the bladder were related to graded toxicity using multivariate ordinal logistic regression. Three models were optimized, each containing all available clinical variables and one of three dose metrics: Mean dose (Dmean), equivalent uniform dose (EUD), or relative volume given x Gy or above (dose cut-off model, Vx). The optimal dose metric was chosen using the Akaike Information Criterion (AIC).

Results: Grade 1 cystitis was experienced by 138 (40%), grade 2 by 39 (11%) and grade 3 by two (1%) patients, respectively. Dose metrics were significantly correlated with toxicity in all models, but the dose cut-off model provided the best AIC value. The only significant clinical risk factors in the Vx model were male gender (p = 0.006) and brachytherapy boost (p = 0.02). Reducing the model to include gender, brachytherapy boost and Vx yielded odds ratios ORmale = 1.82 (1.17-2.80), ORbrachy = 1.36 (1.02-1.80 for each 5 Gy), x = 35.1 Gy (28.6-41.5 Gy). The predicted risk of grade 2 and above cystitis ranged from 2% to 26%.

Conclusion: Acute cystitis correlated significantly with radiation dose to the bladder; the dose-cut-off model (V35Gy) was superior to Dmean and EUD models. Male gender and brachytherapy boost increased the risk of toxicity. Wide variation in predicted risks suggests room for treatment optimization using individual dose constraints.

Citing Articles

Evaluation of Deep Learning Clinical Target Volumes Auto-Contouring for Magnetic Resonance Imaging-Guided Online Adaptive Treatment of Rectal Cancer.

Ferreira Silverio N, van den Wollenberg W, Betgen A, Wiersema L, Marijnen C, Peters F Adv Radiat Oncol. 2024; 9(6):101483.

PMID: 38706833 PMC: 11066509. DOI: 10.1016/j.adro.2024.101483.

Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective Registry.

Pottgen C, Hoffmann C, Gauler T, Guberina M, Guberina N, Ringbaek T Cancers (Basel). 2023; 15(20).

PMID: 37894299 PMC: 10605897. DOI: 10.3390/cancers15204933.

Multiscale spatial relationship-based model for predicting bladder wall dose in pelvic radiotherapy.

Gao X, Ge L, Gao J, Cao Z J Appl Clin Med Phys. 2023; 25(2):e14153.

PMID: 37698358 PMC: 10860549. DOI: 10.1002/acm2.14153.

Effectiveness of bladder filling control during online MR-guided adaptive radiotherapy for rectal cancer.

Feng X, Tang B, Yao X, Liu M, Liao X, Yuan K Radiat Oncol. 2023; 18(1):136.

PMID: 37592338 PMC: 10436664. DOI: 10.1186/s13014-023-02315-3.

Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center.

Zimmermann M, Richter A, Weick S, Exner F, Mantel F, Diefenhardt M Sci Rep. 2022; 12(1):21263.

PMID: 36481692 PMC: 9731986. DOI: 10.1038/s41598-022-25647-8.

References

Wallner C, Lange M, Bonsing B, Maas C, Wallace C, Dabhoiwala N . Causes of fecal and urinary incontinence after total mesorectal excision for rectal cancer based on cadaveric surgery: a study from the Cooperative Clinical Investigators of the Dutch total mesorectal excision trial. J Clin Oncol. 2008; 26(27):4466-72. DOI: 10.1200/JCO.2008.17.3062. View

Bruheim K, Guren M, Skovlund E, Hjermstad M, Dahl O, Frykholm G . Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2009; 76(4):1005-11. DOI: 10.1016/j.ijrobp.2009.03.010. View

Tucker S, Mohan R, Liengsawangwong R, Martel M, Liao Z . Predicting pneumonitis risk: a dosimetric alternative to mean lung dose. Int J Radiat Oncol Biol Phys. 2012; 85(2):522-7. DOI: 10.1016/j.ijrobp.2012.03.052. View

Dorr W, Hendry J . Consequential late effects in normal tissues. Radiother Oncol. 2001; 61(3):223-31. DOI: 10.1016/s0167-8140(01)00429-7. View

Fiorino C, Valdagni R, Rancati T, Sanguineti G . Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol. 2009; 93(2):153-67. DOI: 10.1016/j.radonc.2009.08.004. View

Deasy J, Blanco A, Clark V . CERR: a computational environment for radiotherapy research. Med Phys. 2003; 30(5):979-85. DOI: 10.1118/1.1568978. View

Beetz I, Schilstra C, van Luijk P, Christianen M, Doornaert P, Bijl H . External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. Radiother Oncol. 2011; 105(1):94-100. DOI: 10.1016/j.radonc.2011.11.006. View

Samuelian J, Callister M, Ashman J, Young-Fadok T, Borad M, Gunderson L . Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2011; 82(5):1981-7. DOI: 10.1016/j.ijrobp.2011.01.051. View

Dorr W, Bentzen S . Late functional response of mouse urinary bladder to fractionated X-irradiation. Int J Radiat Biol. 1999; 75(10):1307-15. DOI: 10.1080/095530099139476. View

10.

Passoni P, Fiorino C, Slim N, Ronzoni M, Ricci V, Di Palo S . Feasibility of an adaptive strategy in preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy: boosting the dose to the shrinking tumor. Int J Radiat Oncol Biol Phys. 2013; 87(1):67-72. DOI: 10.1016/j.ijrobp.2013.05.004. View

11.

Eifel P, Levenback C, Wharton J, Oswald M . Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995; 32(5):1289-300. DOI: 10.1016/0360-3016(95)00118-I. View

12.

Fagerland M, Hosmer D . A goodness-of-fit test for the proportional odds regression model. Stat Med. 2012; 32(13):2235-49. DOI: 10.1002/sim.5645. View

13.

Zelefsky M, Levin E, Hunt M, Yamada Y, Shippy A, Jackson A . Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70(4):1124-9. DOI: 10.1016/j.ijrobp.2007.11.044. View

14.

Appelt A, Ploen J, Vogelius I, Bentzen S, Jakobsen A . Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2012; 85(1):74-80. PMC: 3539741. DOI: 10.1016/j.ijrobp.2012.05.017. View

15.

Karlsdottir A, Johannessen D, Paul Muren L, Wentzel-Larsen T, Dahl O . Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol. 2004; 71(1):43-53. DOI: 10.1016/j.radonc.2004.01.014. View

16.

Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J . Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys. 2007; 69(4):1100-9. DOI: 10.1016/j.ijrobp.2007.04.076. View

17.

Deasy J, Muren L . Advancing our quantitative understanding of radiotherapy normal tissue morbidity. Acta Oncol. 2014; 53(5):577-9. PMC: 4795162. DOI: 10.3109/0284186X.2014.907055. View

18.

Marks L, Carroll P, Dugan T, Anscher M . The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995; 31(5):1257-80. DOI: 10.1016/0360-3016(94)00431-J. View

19.

Arbea L, Ramos L, Martinez-Monge R, Moreno M, Aristu J . Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010; 5:17. PMC: 2845593. DOI: 10.1186/1748-717X-5-17. View

20.

Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K . ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012; 23(10):2479-2516. DOI: 10.1093/annonc/mds236. View